Aktiespot

Immunome, Inc. aksje

IMNM

Stengt
$18.58-1.10 (-5.59%)
Laster graf...
Immunome, Inc. logo

Immunome, Inc.

Åpning19.56
Høy19.80
Lav18.56
Volum895.61k
P/EN/A
Markedsverdi2.1B
52-ukers høy27.65
52-ukers lav7.96
Gj.sn. volum1.23M
UtbytteN/A
Beta2.07
EPS-2.39

Om Immunome, Inc. aksje

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Selskapsinformasjon

Børs: NasdaqCM (NCM)
Sektor: Sundhed
Industri: Bioteknologi
Adresse:
18702 North Creek Parkway
98011 Bothell, United States
Telefon: + 425 939 7410

Analytikernes aksjeanbefalinger

Denne oversikten gir et raskt innblikk i hvordan analytikere vurderer aksjens potensial basert på deres siste analyser og kursmål.

Anbefaling:1.21 - Stærk køb
Laveste kursmål
30.00
61.5%
Gjennomsnittlig kursmål
35.36
90.3%
Median kursmål
35.50
91.1%
Høyeste kursmål
40.00
115.3%

Andre ser også på: